Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.

Yao Neng TeoAdriel Z H TingYao Hao TeoElliot Yeung ChongJoshua Teik Ann TanNicholas L SynAlys Z Q ChiaHow Ting OngAlex Jia Yang CheongTony Yi-Wei LiKian Keong PohTiong Cheng YeoMark Yan-Yee ChanRaymond C C WongPing ChaiChing-Hui Sia

Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2022)

In patients with T2DM, compared with pure SGLT2 inhibitors, combined SGLT1/2 inhibitors demonstrated a lower risk of myocardial infarction and of stroke, but were associated with a higher risk of diarrhea and severe hypoglycemia.

Keyphrases

type diabetes
atrial fibrillation
early onset
metabolic syndrome
adipose tissue
skeletal muscle
insulin resistance